GlassScriptPhysician profile
Usha R Vyas
NPI 1972074821
$1,595.45
in general payments reported to CMS, 2019-2025
18 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $481 · 2023: $306 · 2024: $214 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $744.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $282.83 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $204.91 | 2021-2023 | Xarelto |
| Medtronic, INC. | $170.84 | 2024 | Selectsecure, Azure Xt Dr Mri Surescan |
| Heartflow, INC. | $167.45 | 2025 | |
| Sanofi-Aventis U.S. LLC | $136.80 | 2021-2023 | |
| Boston Scientific Corporation | $115.43 | 2023-2025 | Accolade Sr, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $88.03 | 2021-2023 | Eliquis |
| Pfizer INC. | $78.40 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.05 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.33 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $38.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.18 | 2021-2022 | |
| Abbott Laboratories | $31.95 | 2022 | |
| Amgen INC. | $29.85 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $26.44 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $24.50 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $23.77 | 2022 | |
| Irhythm Technologies, INC. | $23.68 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Vyas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.